23 related articles for article (PubMed ID: 8330391)
1. An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies.
Saga T; Ishiwata I; Endo K; Sakahara H; Koizumi M; Watanabe Y; Nakai T; Hosono M; Ishikawa H; Sawada M
Jpn J Cancer Res; 1990 Nov; 81(11):1141-8. PubMed ID: 2125039
[TBL] [Abstract][Full Text] [Related]
2. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells.
Matsuoka Y; Nakashima T; Endo K; Yoshida T; Kunimatsu M; Sakahara H; Koizumi M; Nakagawa T; Yamaguchi N; Torizuka K
Cancer Res; 1987 Dec; 47(23):6335-40. PubMed ID: 3315184
[TBL] [Abstract][Full Text] [Related]
3. Construction of an immunoradiometric assay for ovarian cancer associated antigen CA125 recognizing different antigenic determinant.
Saga T; Endo K; Nakashima T; Awaji T; Koizumi M; Kawamura Y; Watanabe Y; Konishi J; Nonogaki H; Nanbu Y
Acta Obstet Gynecol Scand; 1990; 69(2):175-81. PubMed ID: 1696770
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
Kobayashi H; Ohi H; Fujii T; Terao T
Br J Cancer; 1993 Feb; 67(2):237-43. PubMed ID: 7679280
[TBL] [Abstract][Full Text] [Related]
5. [Basic study of CA125 measurement using a newly developed "SD-8729" IRMA kit].
Yamaguchi A; Kobayashi M; Imai T; Otake H; Matsubara K; Hatori N; Tomiyoshi K; Inoue T; Endo K
Kaku Igaku; 1993 Oct; 30(10):1245-52. PubMed ID: 8264116
[TBL] [Abstract][Full Text] [Related]
6. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
8. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
9. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers in epithelial ovarian cancer.
Saksela E
Int J Gynecol Pathol; 1993 Apr; 12(2):156-61. PubMed ID: 8463040
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125.
Kobayashi H; Tamura M; Satoh T; Terao T
Clin Biochem; 1993 Jun; 26(3):213-9. PubMed ID: 8330391
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
